Novartis AG
ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
Last updated:
Abstract:
Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
Status:
Application
Type:
Utility
Filling date:
23 Oct 2020
Issue date:
16 Sep 2021